Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

SAGE Therapeutics

Biotech & Life Sciences · Raleigh, United States · Founded 2010 · IPO 2014 Unicorn

Develops and delivers novel medicines for most debilitating and disabling central nervous system disorders

Valuation
$100–500M
Latest valuation · 2026
Unlock exact value
Revenue
$10–50M
Latest reported FY
Unlock exact value
Headcount
100–500
Current team size
Unlock exact value
Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

5 investors on SAGE Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Third Rock Ventures
Series B+ 4 investors entered at this stage
OrbiMed
EcoR1 Capital
Foresite Capital
ARCH Venture Partners

SAGE Therapeutics mafia

Startups founded by SAGE Therapeutics alumni

Former SAGE Therapeutics employees who went on to start their own companies. Sorted by Dealroom signal score.

Model MedicinesEst. 2019
SRSean RussellUnited States
Signal score75
Voyager TherapeuticsEst. 2014
Steven PaulUnited States
Signal score65
Nido BiosciencesEst. 2018
Jamil BegUnited States
Signal score61
Tortugas NeuroscienceEst. 2024
JJJeffrey JonasUnited States
Signal score55

Book a demo to explore the full alumni network →

Global footprint

Where SAGE Therapeutics has talent and traffic

AI talent share
2.9% of workforce is AI talent
(6 of 206 staff)
Core AI00%
Other AI62.91%
Non-AI workforce20097.09%
Workforce by country
4 countries with
team presence
🇺🇸 United States97.5%
🇬🇧 United Kingdom1%
🇨🇦 Canada0.7%
🇪🇬 Egypt0.4%
4 countries shown
Web traffic by country
4.3K monthly visits
across markets
🇺🇸 United States67.4%
🇮🇳 India32.6%
Top 2 markets shown

Patent intelligence

$289M patent portfolio · 129 active families

Estimated portfolio value
$289M
151.3% of valuation · comparable to top peer Reata Pharmaceuticals ($354M)
129 active patent families
Where SAGE Therapeutics innovates Medicinal chemistryPharmaceutical medicineSteroidPharmacologyNeuroactive steroid

Where SAGE Therapeutics concentrates vs peers

Each axis is a top-10 topic across SAGE Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about SAGE Therapeutics

An AI-synthesized read of the highest-engagement posts about SAGE Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See SAGE Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles